Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients

Fig. 2

Kaplan-Meier survival curves for three groups. a Overall survival (OS) and b recurrence-free survival. Patients in the Responder group had a more favorable prognosis than patients in the Non-responder group (3-year OS and recurrence-free survival: 50.6 and 39.9%, and 41.6 and 20.2%, respectively, P = 0.026 and P = 0.0621, respectively). The prognosis of the Responder group was comparable to the Normal group, with 3-year OS and recurrence-free survival of 54.2 and 38.9%, respectively (P = 0.934 and P = 0.550, respectively)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us